The Weight-Loss Drug Boom

How GLP-1 drugs like semaglutide became some of the best-selling medicines in history, why they matter for India, and what happens when patents expire.

A class of drugs called GLP-1 receptor agonists, first used for diabetes, turned out to cause major weight loss. Drugs such as semaglutide (sold as Ozempic and Wegovy by Novo Nordisk) and tirzepatide (Mounjaro, by Eli Lilly) became some of the fastest-selling medicines ever.

Why they matter

Obesity and diabetes are rising worldwide, including in India, which has one of the world’s largest numbers of people with diabetes.
These drugs can reduce weight substantially and may lower risks of heart disease.

Economic effects

Company values: Novo Nordisk and Eli Lilly became among the most valuable drug companies in the world.
Health budgets: high prices and huge demand raise concerns about costs for insurers and governments.
Other industries: analysts studied potential effects on food companies, airlines (lighter passengers) and more.

India

Both drugs launched in India in 2025. Prices were high for most Indians. Semaglutide’s patent in India was set to expire in 2026, and many Indian generic makers prepared cheaper versions, which could greatly widen access at home and in other developing countries.

Questions

Long-term effects and side effects.
Weight regain after stopping.
Whether lifestyle changes are neglected.

The generic wave

When a blockbuster drug's patent expires, dozens of Indian firms may launch versions within months. Prices fall sharply, and far more patients can afford treatment.

Thinking weight-loss drugs replace diet and exercise

They are powerful tools, but doctors still recommend healthy eating and activity, and effects may fade if treatment stops.

Key takeaways

GLP-1 drugs like semaglutide and tirzepatide cause major weight loss.
They became some of the best-selling drugs in history.
High prices strain health budgets.
Patent expiry in India opens the way for cheaper generics.